Free Trial
NASDAQ:CLLS

Cellectis (CLLS) Stock Price, News & Analysis

Cellectis logo
$1.89 -0.02 (-1.04%)
(As of 10:02 AM ET)

About Cellectis Stock (NASDAQ:CLLS)

Key Stats

Today's Range
$1.89
$1.90
50-Day Range
$1.75
$2.40
52-Week Range
$1.70
$3.77
Volume
6,385 shs
Average Volume
50,542 shs
Market Capitalization
$105.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
49th Percentile Overall Score

CLLS MarketRank™: 

Cellectis scored higher than 49% of companies evaluated by MarketBeat, and ranked 494th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cellectis has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cellectis' stock forecast and price target.
  • Earnings Growth

    Earnings for Cellectis are expected to decrease in the coming year, from ($0.46) to ($0.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cellectis is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cellectis is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cellectis has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cellectis' valuation and earnings.
  • Percentage of Shares Shorted

    0.28% of the outstanding shares of Cellectis have been sold short.
  • Short Interest Ratio / Days to Cover

    Cellectis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cellectis has recently decreased by 54.96%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cellectis does not currently pay a dividend.

  • Dividend Growth

    Cellectis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.28% of the outstanding shares of Cellectis have been sold short.
  • Short Interest Ratio / Days to Cover

    Cellectis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cellectis has recently decreased by 54.96%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cellectis this week, compared to 1 article on an average week.
  • Search Interest

    Only 3 people have searched for CLLS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cellectis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cellectis' insider trading history.
Receive CLLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

CLLS Stock News Headlines

Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com
Promising Partnership and Pipeline Propel Cellectis SA to a Buy Rating
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Cellectis price target lowered to $5 from $7 at Barclays
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
See More Headlines

CLLS Stock Analysis - Frequently Asked Questions

Cellectis' stock was trading at $3.08 at the start of the year. Since then, CLLS stock has decreased by 38.0% and is now trading at $1.91.
View the best growth stocks for 2024 here
.

Cellectis S.A. (NASDAQ:CLLS) announced its earnings results on Monday, November, 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.03. The biotechnology company had revenue of $18.05 million for the quarter, compared to analysts' expectations of $5 million. Cellectis had a negative trailing twelve-month return on equity of 74.55% and a negative net margin of 234.39%.

Cellectis (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Top institutional investors of Cellectis include Baillie Gifford & Co. (1.25%), Principal Financial Group Inc. (0.74%) and First Affirmative Financial Network (0.04%).

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Alibaba Group (BABA).

Company Calendar

Last Earnings
11/04/2024
Today
11/20/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
5/05/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLLS
Employees
290
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+266.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-101,060,000.00
Net Margins
-234.39%
Pretax Margin
-235.80%

Debt

Sales & Book Value

Annual Sales
$9.19 million
Book Value
$1.52 per share

Miscellaneous

Free Float
46,463,000
Market Cap
$106.16 million
Optionable
Optionable
Beta
3.10

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:CLLS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners